Atopic dermatitis
Atopic dermatitis (AD), also known as atopic eczema, is chronic type of inflammation of the skin.
≈ 10 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Atopic dermatitis (AD), also known as atopic eczema, is chronic type of inflammation of the skin. Atopic dermatitis is also often called simply eczema, but "eczema" is also used to refer to dermatitis, the larger group of skin conditions. Atopic dermatitis results in itchy, red, swollen, and cracked skin.
Clear fluid may come from the affected areas, which can thicken over time. The thickening phenomenon is known as lichenification. Atopic dermatitis affects about 20% of people at some point in their lives.
It is more common in younger children. Females are affected slightly more often than males. Millions of people have outgrown the condition.
While the condition may occur at any age, it typically begins in childhood, with varying severity over the years. In children under one year of age, the face, limbs, and much of the body may be affected. As children get older, the areas on the insides of the knees and folds of the elbows and around the neck are most commonly affected.
In adults, the hands and feet are commonly affected. Scratching the affected areas worsens the eczema and increases the risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma.
The cause is unknown but is believed to involve genetics, immune system dysfunction, environmental exposures, and difficulties with the permeability of the skin.…
Atopic dermatitis (AD), also known as atopic eczema, is chronic type of inflammation of the skin. Atopic dermatitis is also often called simply eczema, but "eczema" is also used to refer to dermatitis, the larger group of skin conditions. Atopic dermatitis results in itchy, red, swollen, and cracked skin.
Clear fluid may come from the affected areas, which can thicken over time. The thickening phenomenon is known as lichenification. Atopic dermatitis affects about 20% of people at some point in their lives.
It is more common in younger children. Females are affected slightly more often than males. Millions of people have outgrown the condition.
While the condition may occur at any age, it typically begins in childhood, with varying severity over the years. In children under one year of age, the face, limbs, and much of the body may be affected. As children get older, the areas on the insides of the knees and folds of the elbows and around the neck are most commonly affected.
In adults, the hands and feet are commonly affected. Scratching the affected areas worsens the eczema and increases the risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma.
The cause is unknown but is believed to involve genetics, immune system dysfunction, environmental exposures, and difficulties with the permeability of the skin. If one identical twin is affected, the other has an 85% chance of having the condition. Those who live in cities and dry climates are more commonly affected.
Exposure to certain chemicals or frequent hand washing makes symptoms worse. While emotional stress may make the symptoms worse, it is not a cause. The disorder is not contagious.
A diagnosis is typically based on the signs, symptoms, and family history. Treatment involves avoiding things that make the condition worse, enhancing the skin barrier through skin care, and treating the underlying skin inflammation. Moisturising creams are used to make the skin less dry and prevent AD flare-ups.
Anti-inflammatory corticosteroid creams are used to control flare-ups. Creams based on calcineurin inhibitors (tacrolimus or pimecrolimus) may also be used to control flares if other measures are not effective. Certain antihistamine pills might help with itchiness.
Things that commonly make the condition worse include house dust mite, stress, and seasonal factors. The material of clothing worn from day-to-day can also make a difference—synthetic fabrics and wool are frequently found to aggravate conditions. Phototherapy may be useful in some people.
Antibiotics (either by mouth or topically) are usually not helpful unless there is secondary bacterial infection or the person is unwell. Dietary exclusion does not benefit most people, and it is only needed if food allergies are suspected. More severe AD cases may need systemic medicines such as ciclosporin, methotrexate, dupilumab, or baricitinib.
Other names of the condition include "infantile eczema", "flexural eczema", "prurigo Besnier", "allergic eczema", and "neurodermatitis".
Climate
Low humidity and low temperature increase the prevalence and risk of flare-ups in people with atopic dermatitis.
Role of Staphylococcus aureus
Colonization of the skin by the bacterium S. aureus is prevalent in those with atopic dermatitis. Abnormalities in the skin barrier of persons with AD are exploited by S. aureus to trigger cytokine expression, thus aggravating the condition. However, atopic dermatitis is non-communicable and therefore could not be directly caused by a highly infectious organism.
Furthermore, there is insufficient evidence for the effectiveness of anti-staphylococcal treatments for treating S. aureus in infected or uninfected eczema. The role of S. aureus in skin irritation occurs via inflammation factors that induce itching, which may damage the skin, further driving inflammation, and facilitating the growth of S. aureus, thus promoting a chronic cycle.
Pathophysiology
Excessive type 2 inflammation underlies the pathophysiology of atopic dermatitis. Disruption of the epidermal barrier is thought to play an integral role in the pathogenesis of AD. Disruptions of the epidermal barrier allows allergens to penetrate the epidermis to deeper layers of the skin.
This leads to activation of epidermal inflammatory dendritic and innate lymphoid cells, which subsequently attract Th2 CD4+ helper T cells to the skin. This dysregulated Th2 inflammatory response is thought to lead to the eczematous lesions.
The Th2 helper T cells become activated, leading to the release of inflammatory cytokines including IL-4, IL-13, and IL-31 which activate downstream Janus kinase (Jak) pathways. The active Jak pathways lead to inflammation and downstream activation of plasma cells and B lymphocytes, which release antigen-specific IgE, contributing to further inflammation.
Other CD4+ helper T-cell pathways thought to be involved in atopic dermatitis inflammation include the Th1, Th17, and Th22 pathways. Some specific CD4+ helper T-cell inflammatory pathways are more commonly activated in specific ethnic groups with AD (for example, the Th-2 and Th-17 pathways are commonly activated in Asian people) possibly explaining the differences in phenotypic presentation of atopic dermatitis in specific populations.
Mutations in the filaggrin gene, FLG, also cause impairment in the skin barrier that contributes to the pathogenesis of AD. Filaggrin is produced by epidermal skin cells (keratinocytes) in the horny layer of the epidermis.
Filaggrin stimulates skin cells to release moisturizing factors and lipid matrix material, which cause adhesion of adjacent keratinocytes and contribute to the skin barrier. A loss-of-function mutation of filaggrin causes loss of this lipid matrix and external moisturizing factors, subsequently leading to disruption of the skin barrier.
The disrupted skin barrier leads to transdermal water loss (leading to the xerosis or dry skin commonly seen in AD) and antigen and allergen penetration of the epidermal layer. Filaggrin mutations are also associated with a decrease in natural antimicrobial peptides found on the skin; subsequently leading to disruption of skin flora and bacterial overgrowth (commonly Staphylococcus aureus overgrowth or colonization).
Atopic dermatitis is also associated with the release of pruritogens (molecules that stimulate pruritus or itching) in the skin. Keratinocytes, mast cells, eosinophils and T-cells release pruritogens in the skin; leading to activation of Aδ fibers and Group C nerve fibers in the epidermis and dermis contributing to sensations of pruritus and pain.
The pruritogens include the Th2 cytokines IL-4, IL-13, IL-31, histamine, and various neuropeptides. Mechanical stimulation from scratching lesions can also lead to the release of pruritogens contributing to the itch-scratch cycle, whereby there is increased pruritus or itch after scratching a lesion.
Chronic scratching of lesions can cause thickening or lichenification of the skin or prurigo nodularis (generalized nodules that are severely itchy). Another factor in the barrier failure and immunological dysregulation in people with atopic dermatitis may be due to decreases in tight junction protein Claudin-1.
Inhibiting Claudin-1 expression in human keratinocytes has been shown to both reduce tight junction function, as well as increase keratinocyte proliferation in vitro. It has also been discovered that this deteriorates the bioelectric barrier function in the epidermis.
Diet
The role of vitamin D on atopic dermatitis is not clear, but vitamin D supplementation may improve its symptoms. There is no clear benefit for pregnant mothers taking omega 3 long-chain polyunsaturated fatty acid (LCPUFA) in preventing the development of AD in their child. Several probiotics seem to have a positive effect, with a roughly 20% reduction in the rate of AD.
Probiotics containing multiple strains of bacteria seem to work the best. In people with celiac disease or nonceliac gluten sensitivity, a gluten-free diet improves their symptoms and prevents the occurrence of new outbreaks. Use of blood-specific IgE or skin prick tests to guide dietary exclusions to improve disease severity or control is controversial.
Clinicians vary in their use of these tests for this purpose, and there is very limited evidence of any benefit.
Lifestyle
Health professionals often recommend that people with AD bathe regularly in lukewarm baths, especially in saltwater, to moisten their skin. Dilute bleach baths may be helpful for people with moderate and severe eczema, but only for people with Staphylococcus aureus.
Avoiding large-diameter woolen clothing or scratchy fibres is usually recommended for people with AD as they can trigger a flare. Safe alternatives are clothes made from fabrics with smaller diameters and smooth fibers. These include super- and ultrafine merino wool and fabrics with anti-microbial textile finishes.
Wearing silk is also safe but does not improve symptoms of AD.
Light
Phototherapic treatment involves exposure to broad- or narrow-band ultraviolet (UV) light. UV radiation exposure has been found to have a localized immunomodulatory effect on affected tissues and may be used to decrease the severity and frequency of flares.
Among the different types of phototherapies only narrowband (NB) ultraviolet B (UVB) exposure might help with the severity of AD and ease itching. However, UV radiation has also been implicated in various types of skin cancer, and thus UV treatment is not without risk.
UV phototherapy is not indicated in young adults and children due to this risk of skin cancer with prolonged use or exposure.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1364329717 under CC BY-SA 4.0; modifications have been made.